Watch Live

Tweet TWEET

GE Healthcare and Eisai Inc. to Partner on Alzheimer’s Disease Research

  GE Healthcare and Eisai Inc. to Partner on Alzheimer’s Disease Research

        Eisai Initiates Phase I Trial of BACE Inhibitor Utilizing GE’s
                              [^18F]Flutemetamol

Business Wire

CHALFONT ST. GILES, England -- April 24, 2013

GE Healthcare today announced a research collaboration agreement with Eisai
Inc. for use of the GE Healthcare investigational PET amyloid imaging agent,
[^18F]flutemetamol, to help select patients for a phase I clinical trial being
conducted by Eisai. The trial evaluates Eisai’s investigational compound
E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor
for the potential treatment of Alzheimer’s disease (AD). The accumulation of
beta amyloid in the brain is believed to play a role in the degeneration of
neurons and is one of several pathological characteristics implicated in the
development of AD.

“Alzheimer’s disease is an important area of research for the industry and
specifically for GE Healthcare,” said Pascale Witz, President and CEO of GE
Healthcare, Medical Diagnostics. “This partnership may ultimately support the
market entry of important therapies, and potentially, expedited time to market
because the right patients have been identified for participation in clinical
trials. Under terms of the agreement, GE Healthcare’s proprietary software
technology will be used during the trial to help support imaging data
analysis.”

"Eisai has a long-standing commitment to Alzheimer's disease," said Lynn
Kramer, MD, Chief Clinical Officer and President of the Neuroscience and
General Medicine Product Creation Unit at Eisai Product Creation Systems.
"Imaging plays a key role in our efforts to better understand the progression
of the disease and identify potential patients for our clinical trials.
Through this collaboration, Eisai hopes to bring important new treatment
options to patients and caregivers who are affected by this devastating
disease."

GE Healthcare takes a comprehensive approach to understanding a variety of
neurological disorders such as Alzheimer’s disease, Parkinson’s disease,
post-traumatic stress disorder, concussion, traumatic brain injury and
Multiple Sclerosis through its ongoing research to uncover the causes, risks,
and physical effects of these conditions. By collaborating with the
pharmaceutical industry to assist in their development of the next generation
of therapies to treat these disorders and working with potential partners in
the industry, GE Healthcare can provide imaging support for clinical trials of
therapeutic agents.

For more information about Eisai’s Phase I trial, which is currently
recruiting participants, please visit www.ClinicalTrials.gov.

ABOUT GE HEALTHCARE

GE Healthcare provides transformational medical technologies and services to
meet the demand for increased access, enhanced quality and more affordable
healthcare around the world. GE (NYSE: GE) works on things that matter - great
people and technologies taking on tough challenges. From medical imaging,
software & IT, patient monitoring and diagnostics to drug discovery,
biopharmaceutical manufacturing technologies and performance improvement
solutions, GE Healthcare helps medical professionals deliver great healthcare
to their patients.

For our latest news, please visit http://newsroom.gehealthcare.com

Contact:

GE Healthcare
Aleisia Gibson
609 514 6046 (office)
201 289 3832 (mobile)
Aleisia.gibson@ge.com
 
Press spacebar to pause and continue. Press esc to stop.